Pharmafile Logo
Pharmafocus logo
Advanced Search

Rituxan

Showing 15 posts of 15 posts found.

roche__tree

Roche’s Phase 3 Pemphix trial smashes primary endpoint for pemphigus vulgaris

October 14, 2019
Research and Development, Sales and Marketing MabThera, Rituxan, Roche, pharma

Roche has revealed new Phase 3 data demonstrating that its MabThera/Rituxan (rituximab) therapy Pemphix met its primary endpoint in the …

News

Roche secures US paediatric approval for Rituxan in two rare forms of vasculitis

September 30, 2019
Sales and Marketing MabThera, Rituxan, Roche, pharma, vasculitis

Roche has revealed that Rituxan (rituximab), also known as MabThera, has been awarded US approval from the FDA in combination …

News
fda2outsideweb

FDA approves Pfizer’s biosimilar version of Genentech’s Rituxan

July 24, 2019
Research and Development FDA, Pfizer, Rituxan, Ruxience, biosimilars, pharma

Pfizer has seen Ruxience, its biosimilar version of Genentech’s Rituxan (rituximab), approved by the FDA in the treatment of non-Hodgkin …

News

FDA approves first Rituxan biosimilar courtesy of Teva and Celltrion

November 29, 2018
Sales and Marketing FDA, Genentech, Rituxan, Roche, Teva, Truxima, biosimilars, celltrion

The FDA has announced the first US approval of a biosimilar version of Genentech’s Rituxan (rituximab), awarding marketing approval to …

News
image_readtop_2018_569751_15365546683454581

Celltrion’s Rituxan biosimilar gets unanimous backing from FDA committee

October 11, 2018
Sales and Marketing FDA, Oncologic Drugs Advisory Committee, Rituxan, Roche, Truxima

FDA approval looks to be in reach for Celltrion, as an advisory committee for the US regulator voted unanimously to …

News
acute_leukemia-all

Roche and AbbVie’s leukaemia combo smashes Phase 3 endpoint

September 19, 2017
Manufacturing and Production, Research and Development AbbVie, Rituxan, Roche, Venclexta, Venclyxto, leukaemia, pharma, pharmaceutical

Venclexta/Venclyxto (venetoclax), Roche and AbbVie’s oral B-cell lymphoma-2 (BCL-2) inhibitor, successfully met its primary endpoint in Phase 3 trials, providing …

News

FDA accepts license application for Novartis’ rituximab biosimilar

September 12, 2017
Manufacturing and Production, Sales and Marketing Novartis, Rituxan, Sandoz, biosimilar, rituximab

Sandoz, Novartis’ generics and biosimilars division, has revealed that the FDA has accepted its Biologics License Application (BLA) for a …

News
novartis_window

Novartis receives European biosimilar approval for Roche blockbuster

June 19, 2017
Sales and Marketing Novartis, Rituxan, Rixathon, Roche

Sandoz, a division within Novartis, has received European Commission approval for its biosimilar version of Roche’s Rituxan (also known as …

News
Roche image

Roche buoyed by cancer drug sales

April 22, 2015
Sales and Marketing Actemra, Cancer, Esbriet, Esbriet., MabThera, Q1, Rituxan, RoActemra, Roche, Xolair, avastin, oncology

Pharma’s biggest cancer drugs maker Roche has reported strong sales growth on the back of its oncology portfolio for its …

News
Roche image

Strong growth for Roche in latest results

July 25, 2013
Sales and Marketing Alexion, Q2, Rituxan, Roche

Roche has seen strong sales growth in the past six months as it lines up new products to replace its …

News
Roche image

New Roche leukaemia drug beats rival

July 24, 2013
Research and Development, Sales and Marketing Rituxan, Roche, leukaemia, obinutuzumab

Roche’s next generation leukaemia drug obinutuzumab has beaten the firm’s ageing blood cancer medicine Rituxan in a late-stage trial. The …

News
Roche's MabThera

NICE recommends MabThera for non-Hodgkin’s lymphoma

December 6, 2010
Sales and Marketing MabThera, NICE, Rituxan, Roche, non-Hodgkin’s lymphoma, rituximab

NICE has given a preliminary green-light to Roche’s MabThera for use as a maintenance therapy for non-Hodgkin’s lymphoma. The Institute’s …

News

Biogen set to axe 650 jobs and focus on neurology

November 4, 2010
Research and Development, Sales and Marketing Biogen, Rituxan, job cuts, pharma jobs

Biogen Idec is set to cut hundreds of jobs and refocus its R&D in an effort to cut costs by …

News

MabThera gains maintenance therapy licence

October 29, 2010
Medical Communications, Sales and Marketing MabThera, Rituxan, Roche, lymphoma

Roche’s MabThera has been approved as a maintenance therapy for follicular lymphoma, a common type of blood cancer. Maintenance treatment …

News

Rituxan gains approval for most common leukaemia

February 19, 2010
Sales and Marketing FDA, MabThera, Rituxan, blood cancer

Roche’s blockbuster cancer treatment MabThera/Rituxan has been approved by the FDA for the treatment of adult leukaemia. The drug earned …

News

Latest content

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024

FDA approves ImmunityBio’s Anktiva bladder cancer treatment

April 23, 2024

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

April 22, 2024

Neurolentech and Kaerus Bioscience enter partnership for research on neurodevelopmental disorder

April 22, 2024

Ardena announces €20m expansion following first GMP approval

April 19, 2024